Author

A. L. Lim

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

B. W. Miller· 1 shared C. D. Pond· 1 shared E. C. Larson· 1 shared E. Schmidt· 1 shared L. L. Martins· 1 shared L. R. Barrows· 1 shared M. A. Szaniawski· 1 shared M. G. Haygood· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

B. W. Miller

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

HIV-1 provirus transcription and translation in macrophages differs from macrophages containing pre-integrated cDNA complexes and requires E2F transcriptional programs

A. L. Lim, P. Moos, C. D. Pond, E. C. Larson, L. L. Martins, M. A. Szaniawski, V. Planelles, L. R. Barrows

The paper compares HIV-1 transcription from pre-integrated cDNA and integrated provirus in macrophages using scRNA-seq, finding that provirus transcription correlates with viral protein production and E2F transcriptional programs.

Virulence · Feb 15, 2022Peer-reviewedMicrobiology

Initial efficacy determination and resistance profile of anti-Acinetobacter antibiotics, turnercyclamycins

B. W. Miller, A. L. Lim, M. G. Haygood, E. Schmidt

This study evaluates the efficacy and resistance profile of turnercyclamycins against Acinetobacter, showing high potency and reduced resistance compared to colistin.

bioRxiv · Nov 1, 2021 · PreprintPharmacology & Toxicology